4.5 Article

The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model

Journal

INTERNATIONAL JOURNAL FOR PARASITOLOGY
Volume 45, Issue 4, Pages 203-207

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijpara.2014.12.006

Keywords

Atherosclerosis; ES-62; Helminth; Systemic lupus erythematosus

Categories

Funding

  1. Wellcome Trust, UK [086852]
  2. National Institutes of Health (NIH), USA [PO1 R050256]
  3. US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)/NIH [K01 AR055965-02]
  4. NIAMS/NIH [R21 AR063387-01]

Ask authors/readers for more resources

ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus eiythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus. (C) 2015 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available